Evidence map›Paper›PMID 34939012›Full record

ArticleKidney medicine

Prostate Cancer, Kidney Transplant Wait Time, and Mortality in Maintenance Dialysis Patients: A Cohort Study Using Linked United States Renal Data System Data.

Nagaraju Sarabu, Nicholas Schiltz, Kenneth J Woodside, Anne M Huml, Ashwini R Sehgal, Simon Kim, Donald E Hricik

Open access · goldAbstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Nagaraju SarabuDivision of Nephrology, Department of Medicine, University Hospitals, Cleveland, OH.
Nicholas SchiltzDepartment of Population & Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH.
Kenneth J WoodsideDepartment of Surgery, University of Michigan, Ann Arbor, MI.
Anne M HumlDivision of Nephrology, Department of Medicine, MetroHealth Medical Center, Cleveland, OH.
Ashwini R SehgalDivision of Nephrology, Department of Medicine, MetroHealth Medical Center, Cleveland, OH.
Simon KimDepartment of Urology, University of Colorado, Aurora.
Donald E HricikDivision of Nephrology, Department of Medicine, University Hospitals, Cleveland, OH.
MetroHealth Medical Center · USUniversity Hospitals of Cleveland · USCase Western Reserve University · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan–Ann Arbor · US

Funding

Barriers to Care for Patients Transitioning from Transplant to DialysisK23DK101492 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI HUML, ANNE MARIE · 2016 to 2020
$800k
NIDDK NIH HHS K23 DK101492
6 · The paper itself

Abstract

RATIONALE &

objectiveThe impact of prostate cancer on mortality in patients with end-stage kidney disease may be different from the general population. Prostate cancer may also delay the kidney transplant but has not been studied in a population-based cohort. We examined how prostate cancer influenced time to kidney transplant and death in a dialysis population. STUDY

designRetrospective population-based, risk-set propensity score-matched cohort study. SETTING &

participantsMen, 40-79 years old, who were dialysis-dependent Medicare beneficiaries without prior documented prostate cancer, from the United States Renal Data System. EXPOSURES: Incident prostate cancer, identified using OUTCOMES: Time to kidney transplant and death. ANALYTICAL APPROACH: Propensity-based risk-set matching to reduce bias between cases and controls. Cox proportional hazards model for time to death, and Fine-Gray competing risk model for time to kidney transplant.

resultsAmong a total of 588,478 male dialysis patients who met the eligibility criteria, 18,162 had claims for prostate cancer. After propensity-based risk-set matching, 15,554 pairs of prostate cancer cases and controls were identified. Among the matched pairs, survival rates were 76%, 48%, and 30% at 1, 3, and 5 years in the prostate cancer group, compared with 80%, 51%, and 33% in the control group, with relative mortality of 95%, 94%, and 91% respectively (log-rank test LIMITATIONS: Retrospective registry study.

conclusionsProstate cancer is associated with a modest increase in the risk of death and time to transplant in patients with end-stage kidney disease. Kidney transplant is associated with the same degree of survival benefit among those with pretransplant prostate cancer as those without.

Indexed as

Dialysiskidney transplantmortalitypropensity matchingprostate cancerwaiting time

Identifiers

PMID34939012
PMCPMC8664748
OpenAlexW3202599141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.